CEO of Rare Disease Drug Development Bio Company Purchases Millions in Company Stock

MBX Biosciences, Inc. (NASDAQ: MBX) President and CEO P. Kent Hawryluk purchased approximately 18,500 shares of the company’s common stock at an average price of $28.41 per share through his personal trust on March 13. The transaction totaled about $520,000 (approximately KRW 700 million), bringing the trust’s indirect holdings to roughly 486,000 shares.

On March 9, MBX announced it had successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for its chronic hypoparathyroidism candidate, Canbuparatide, and revealed plans to initiate Phase 3 clinical trials in the third quarter of 2026. On March 10, the company further strengthened its business development team by appointing Karen Basbaum as Chief Business Officer.

MBX Biosciences is a Nasdaq-listed, clinical-stage biopharmaceutical company focused on precision peptide therapeutics for endocrine and metabolic disorders. Its lead pipeline includes Canbuparatide for chronic hypoparathyroidism, along with novel candidates targeting rare metabolic conditions such as post-gastrectomy and post-bariatric surgery hypoglycemia.